Page last updated: 2024-09-04

resiquimod and glycolipids

resiquimod has been researched along with glycolipids in 1 studies

Compound Research Comparison

Studies (resiquimod)	Trials (resiquimod)	Recent Studies (post-2010) (resiquimod)	Studies (glycolipids)	Trials (glycolipids)	Recent Studies (post-2010) (glycolipids)
465	14	318	19,062	170	5,050

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Christensen, D; Lattmann, E; Pedersen, GK; Perrie, Y; Roces, CB; Wilkinson, A	1

Other Studies

1 other study(ies) available for resiquimod and glycolipids

Article	Year
Lipid conjugation of TLR7 agonist Resiquimod ensures co-delivery with the liposomal Cationic Adjuvant Formulation 01 (CAF01) but does not enhance immunopotentiation compared to non-conjugated Resiquimod+CAF01. Journal of controlled release : official journal of the Controlled Release Society, 2018, 12-10, Volume: 291 Topics: Adjuvants, Immunologic; Animals; Female; Glycolipids; Imidazoles; Lipids; Liposomes; Mice, Inbred BALB C; Quaternary Ammonium Compounds; Toll-Like Receptor 7; Vaccines	2018

Article

Year

Lipid conjugation of TLR7 agonist Resiquimod ensures co-delivery with the liposomal Cationic Adjuvant Formulation 01 (CAF01) but does not enhance immunopotentiation compared to non-conjugated Resiquimod+CAF01.

Journal of controlled release : official journal of the Controlled Release Society, 2018, 12-10, Volume: 291

Topics: Adjuvants, Immunologic; Animals; Female; Glycolipids; Imidazoles; Lipids; Liposomes; Mice, Inbred BALB C; Quaternary Ammonium Compounds; Toll-Like Receptor 7; Vaccines

2018